7910 Woodmont Avenue,Suite 1210
Bethesda, Maryland 20814, U.S.A. 
info@mlsvfund.com |   +1 301 298 5455

© 2018  by MASA Life Science Ventures, LP


May 30, 2019

Montreal, Canada - enGene Inc. , the high growth biotechnology company developing the Gene Pill™ - a robust, proprietary non-viral vector platform to deliver gene therapies via oral administration - today announced the appointment of José M. Lora, Ph...

July 17, 2018

Montreal, Canada - enGene Inc. a biotechnology company developing novel non-viral vector gene therapies to provide oral delivery of a wide range of protein drugs, including the Gene Pill™ , today announced the appointment of Jason D. Hanson as Presid...

November 1, 2017

Prestigious Gold Leaf Award recognizes enGene’s leadership and achievements

Montreal, Canada - –enGene Inc.a biotechnology company focused on the development of a proprietary Gene PillTM platform, has been awarded a prestigious Gold Leaf Award and nam...

May 2, 2017

Montreal, Canada - –enGene Inc. announced today that Theresa Podrebarac, MD, has joined the company as Chief Medical Officer. In her new position, Dr. Podrebarac will be responsible for designing and executing clinical development plan for enGene’s p...

April 26, 2017

enGene’s proprietary PD-L1 gene therapy is being developed as potential novel therapy for acute GvHD

Late-breaking abstract on preclinical data from PD-L1 program will be presented at Digestive Disease Week (DDW) 2017 in Chicago 

Montreal, Canada - –en...

January 12, 2016

Osaka, Japan, and Montreal, Canada - –Takeda Pharmaceutical Company Ltd. (TSE: 4502) and enGene, Inc. today announced a strategic alliance to discover, develop and commercialize novel therapies for specialty gastrointestinal (GI) diseases using enGen...

December 9, 2015

Montreal, Canada –- enGene, Inc., a gene therapy company focused on development of therapeutics using its proprietary “Gene Pill” and enema gene delivery platform, today announced the appointment of Dr. Dennis H. Langer to its Board of Directors.


October 15, 2015

Montreal, Canada - enGene, Inc. a gene therapy company focused on development of therapeutics using its proprietary “Gene Pill” and enema gene delivery platform, today announced that it has entered into a definitive agreement with Janssen Biotech, In...

January 26, 2015

Montreal, Canada - enGene Inc., A Montréal-based biotechnology enterprise developing an innovative platform technology for delivering genes to cells lining the gastrointestinal tract, announced today the closing of a $13.5 million Series B investment...

August 1, 2013

Toronto - enGene Inc., a pre-clinical stage biopharmaceutical company developing a platform technology for the robust delivery of nucleotides (DNA or RNA) to the gut, announced today that it has completed an initial closing of a $13.25 million financ...

Please reload

Featured Posts
Please reload

See News By Company
See News By Month
Please reload